At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Repaglinide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of LOXO-292 on the Single Dose Pharmacokinetics of Repaglinide in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating Repaglinide and Selpercatinib for Healthy. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The main purpose of this study is to assess the effect of selpercatinib on how fast repaglinide gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to 12 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLoxo Oncology, Inc.
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
Primary CompletionMar 2019
First PostedJul 2022
TodayJul 2026
First PostedJul 21, 2022
Enrollment StartJan 29, 2019
Primary CompletionMar 5, 2019
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 3.9 years ago
Interventions
Repaglinidedrug
Administered orally.
Selpercatinibdrug
Administered orally.